Crucell reports a nonexclusive STAR® research license agreement with Korean-based ISU ABXIS. The rights cover both a research evaluation of this technology for the production of recombinant proteins and an option for a commercial license.
STAR is a production platform that is used for recombinant human antibodies and proteins. It can also be used to produce antibodies and proteins on mammalian cell lines. The technology contains genetic elements called STAR elements that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells, according to Crucell.